• Sales grow 13.8% in local currency and pass the 200 million CHF threshold
• EBIT margin of 18.5% and EBITDA margin of 27.2%
• Net income increases 9.5% to 31.8 million CHF
• Market leadership extended and American Peptide Company integrated
• About 80 new jobs created in Switzerland; expansion at all company sites
• Increase in dividend from 2.00 to 2.25 CHF proposed
• Healthy order backlog, further sustainable growth expected

Bubendorf/Basel, March 11, 2016 – Bachem Group (SIX: BANB), the market leader in the field of peptide chemistry with a distinctive focus on quality and innovation, looks back on a successful fiscal year. Group sales reached a new record high of 208.6 million CHF (2014: 183.9 million CHF, +13.4% in CHF and +13.8% in local currency/LC). Excluding last year’s extraordinary gain of 2.0 million CHF on the divestment of the immunology product line, Bachem increased its operating profit (EBIT) for fiscal 2015 by 13.5% to 38.5 million CHF. This figure includes a negative amount of 0.9 million USD in connection with the business activities acquired from American Peptide Company (APC). Despite this one-time effect, Bachem was able to slightly raise its EBIT margin to 18.5% (previous year: 18.4% excluding gain on sale of immunology product line). Earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to 56.8 million CHF (previous year: 55.1 million CHF), which corresponds to a high EBITDA margin of 27.2%. With these figures Bachem completely achieved its sales targets for fiscal 2015 amid a persisting competitive market environment and increased its bottom-line profit significantly to 31.8 million CHF, despite negative currency effects and a negative earnings contribution from APC.